Welcome to our dedicated page for Redhill Biopharm SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings are notoriously dense—especially when they cover multiple Phase 3 trials, FDA correspondence, and royalty structures like RedHill Biopharma’s. If you have ever searched the 300-page annual report for an opaganib trial update or hunted through Form 4s to see whether executives bought shares after a Talicia sales milestone, you know the challenge. Our SEC filings hub solves this pain by pairing every RedHill Biopharma disclosure with AI-powered summaries that explain the jargon in plain English.
You’ll find the complete set of documents—10-K annual report, 10-Q quarterly earnings, 8-K material events, and proxy statements—streaming from EDGAR in real time. Need “RedHill Biopharma insider trading Form 4 transactions” or a quick view of “RedHill Biopharma quarterly earnings report 10-Q filing”? One click shows the original text, an expert synopsis, and key data points. Stock Titan’s algorithms tag R&D expense trends, highlight liquidity discussions, and surface any RedHill Biopharma executive stock transactions Form 4, so you can focus on decision making instead of page turning.
Whether you’re tracking potential FDA approval timelines, comparing segment revenue from Talicia and Aemcolo, or monitoring board compensation, our platform keeps you ahead. Use AI to drill into “RedHill Biopharma proxy statement executive compensation”, receive alerts for “RedHill Biopharma 8-K material events explained”, and explore “RedHill Biopharma earnings report filing analysis” without reading line by line. Understanding RedHill Biopharma SEC documents with AI means faster insights, fewer surprises, and more confident investing.
RedHill Biopharma has filed an F-1 registration statement for a potential offering of up to 5,596,490 American Depositary Shares (ADSs) representing 55,964,900,000 ordinary shares. The offering relates to resale by Alumni Capital LP through an Any Market Purchase Agreement dated June 20, 2025.
Key offering details:
- Committed equity line of credit up to $10 million with Alumni Capital
- Each ADS represents 10,000 ordinary shares
- Includes 5,263,157 AMPA ADSs and 333,333 Commitment Warrant ADSs
- Purchase price varies based on VWAP: 82% for initial purchase, 90% for regular purchases, or 96% for forward purchases
The company is an Israeli-based foreign private issuer trading on Nasdaq under "RDHL". RedHill will not receive proceeds from ADS resales but will receive proceeds from warrant exercises. Alumni Capital is considered an underwriter and subject to a 4.99% ownership limitation. The last reported ADS price was $1.94 on June 24, 2025.
RedHill Biopharma has entered into an Any Market Purchase Agreement with Alumni Capital LP on June 20, 2025, enabling the company to sell up to $10 million in American Depositary Shares (ADSs). Key terms include:
- Initial tranche up to $1 million priced at 82% of lowest 5-day VWAP
- Subsequent regular purchases up to $500,000 or 60% of 5-day average trading volume at 90% of lowest 5-day VWAP
- Additional discretionary purchases up to $500,000 or 30% of same-day trading volume at 96% of lowest traded price
- Commitment Warrants issued to purchaser for 333,333 ADSs with $3.00 exercise price and 5-year term
The agreement includes a 4.99% ownership cap and requires SEC registration effectiveness. The arrangement provides RedHill with flexible funding options through June 30, 2026, subject to market conditions and company discretion.
FAQ
What is the current stock price of Redhill Biopharm (RDHL)?
What is the market cap of Redhill Biopharm (RDHL)?
What is the primary focus of RedHill Biopharma?
Which products does RedHill currently commercialize?
What are some of the key clinical programs in RedHill's pipeline?
How does RedHill differentiate itself in the biopharmaceutical industry?
Why is RedHill considered an expert in clinical-stage drug development?
What makes RedHill Biopharma attractive to investors?
